ClinicalTrials.gg
Enrolling by invitationNCT05712850Updated Jul 24, 2023

Clinical Outcome and Fusion Results Using the SiJoin® Transfixing Sacroiliac Fusion Device

An observational study in Sacroiliitis, Sacroiliac Joint Dysfunction and Iatrogenic Injury, sponsored by VG Innovations, LLC. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-24.

Sponsored by VG Innovations, LLC · Observational

From the registry’s dates

  • Primary completion was expected by Jan 2024, 2 years 9 months ago, but the record still lists the study as enrolling by invitation.
Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
25
Ages
18 Years to 85 Years
Sex
All
01

Study summary

The purpose of this clinical study is to evaluate fusion of the SI joint(s) and any reduction in VAS pain scores in a prospective cohort of patients utilizing the SiJoin® Transfixing Sacroiliac Fusion Device in patients that received sacroiliac fusion, without ancillary stabilization devices.

Read the detailed description

Study Title: A prospective, single arm clinical trial evaluating clinical outcome and fusion results using the SiJoin® Transfixing Sacroiliac Fusion Device

Instrumentation SiJoin® Transfixing Sacroiliac Fusion Device Study Design: Non-randomized, prospective, single arm, single center clinical trial

Patient Population and Sample Size:

Patients (n≥25) from 1 clinical site, who have been medically evaluated, found appropriate for, and have agreed to treatment by sacroiliac joint fixation, including unilateral and/or bilateral sacroiliac fusion according to accepted medical standards using the SiJoin® Transfixing Sacroiliac Fusion Device.

Objectives: The primary objective of this study is:

  1. Evaluate the fusion status of sacroiliac joints at 12 months (depending on patient (vailability) following joint fusion/fixation using the SiJoin® Transfixing Sacroiliac Fusion Device;
  2. Subject success / Clinical outcome: Evaluate the reduction in baseline VAS back pain score at 2-3 weeks, 3 months, and 12 months.

The secondary objectives of this study are to:

  1. Assess the ease of use of the SiJoin® Fusion System;
  2. Document the occurrence of adverse events related or possibly related to the use of the SiJoin® Fusion System;
  3. Document the occurrence of subsequent surgical intervention at the sacroiliac joint.

Inclusion Criteria:

Candidates must meet ALL of the following:

  1. Have provided consent for research by signing the Information and Consent for Research form;
  2. Have given appropriate operative consent for a sacroiliac joint fixation procedure as standard of care using the SiJoin® Transfixing Sacroiliac Fusion Device;
  3. Are skeletally mature male or female, and are at least 18 years of age at time of surgery;
  4. Patient history confirms sacroiliac joint disfunction;
  5. Failure of six months of conservative care;
  6. Failure of NSAIDs;
  7. Positive diagnosis injection of sacroiliac joint; and
  8. Agree to adhere to post-surgical medically prescribed activity limitations and/or physical rehabilitation.

Exclusion Criteria:

Candidates will be excluded if they have ANY of the following:

  1. Previous surgery or prior hardware in place at the target sacroiliac joint;
  2. Deidentified data cannot be provided;
  3. If female, pregnant at time of sacroiliac joint surgery;
  4. Found to be inappropriate candidate for sacroiliac joint fixation;
  5. Requires additional and/or other surgical technique and/or approach to the sacroiliac joint, which may in the opinion of the Primary Investigator confound measurement of outcome variables;
  6. Has a medical disorder or is receiving medications that would be expected to interfere with osteogenesis;
  7. Has active malignancy, or patient with a history of any malignancy (except non-melanoma skin cancer) with recurrence within 5 years or surgery;
  8. Has active local or systemic infection or history of local or systemic infection, immune-deficiency, uncontrolled medical conditions, which in the opinion of the Investigator may increase patient risk or confound fusion results;
  9. Has BMI >40%;
  10. Has history of tobacco smoking within 6 months prior to operation;
  11. Has history of alcoholism, medication or drug abuse, psychosis, is a prisoner, and/or has a personality disorder, poor motivation, emotional or intellectual issues that would likely make the patient unreliable for participation in the study;
  12. Has history of diabetes;
  13. Are participating in any other clinical trial;
  14. Patient is an employee (or family members of employees) of the PI/site or Sponsor; or
  15. Patient is limited or non-reader (e.g., blind, illiterate) Study Duration: 12 months

Study Outcomes:

The primary study outcomes of this study are:

  1. Fusion grade at 12 months follow-up (depending on patient availability) using CT scans with a grading system based on:

    1. Complete fusion; or
    2. No fusion.
  2. Subject success / Clinical outcome: Evaluate the reduction in baseline VAS back pain score at:

    1. 2-3 weeks;
    2. 3 months; and
    3. 12 months.

The secondary outcomes of this study are:

  1. Surgeon opinion of "ease of use" utilizing the SiJoin® Fusion System;
  2. Occurrence of adverse events related or possibly related to the use of the SiJoin® Fusion System; and
  3. Occurrence of subsequent surgical intervention at the target joint.

Study Assessments

  • Intraoperative: Post-placement radiograph;
  • 12 month: sacroiliac joint CT scan;
  • Patient provided VAS pain scores at pre-op, and each subsequent follow-up appointment.
02

Conditions studied

  • Sacroiliitis
  • Sacroiliac Joint Dysfunction
  • Iatrogenic Injury
  • Osteitis Condensans Ilii
  • Pelvic Fracture
03

In context

Sacroiliitis

42 studies on the registry are indexed under Sacroiliitis; 11 are open to participants now.

This study's planned enrollment of 25 is below the median of 120 across 13 observational studies indexed under Sacroiliitis.

Browse Sacroiliitis studies →

Lead sponsor

VG Innovations, LLC is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients who have been evaluated and found appropriate for SI joint fixation according to accepted medical standards, and have agreed to this surgical procedure will be considered for study enrollment. Only those patients judged by the surgeon (intra-operatively) to be suitable for SI joint fixation using the SiJoin® Transfixing Sacroiliac Fusion Device will be included in data collection.

Study patients will be identified and recruited from outpatient facilities affiliated with investigative sites. For the purposes of enrollment, patients will only be considered evaluable study patients after they complete eligibility screening and sign the study Information and Consent for Research Form.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have provided consent for research by signing the Information and Consent for research form;
  2. Have given appropriate operative consent for a sacroiliac joint fixation procedure as standard of care using the SiJoin® Transfixing Sacroiliac Fusion Device;
  3. Are skeletally mature male or female, and are at least 18 years of age at time of surgery;
  4. Patient history confirms sacroiliac joint disfunction;
  5. Failure of six months of conservative care;
  6. Failure of NSAIDs;
  7. Positive diagnosis injection of sacroiliac joint; and
  8. Agree to adhere to post-surgical medically prescribed activity limitations and/or physical rehabilitation.

Exclusion criteria

Exclusion Criteria:

  1. Previous surgery or prior hardware in place at the target sacroiliac joint;
  2. Deidentified data cannot be provided;
  3. If female, pregnant at time of sacroiliac joint surgery;
  4. Found to be inappropriate candidate for sacroiliac joint fixation;
  5. Requires additional and/or other surgical technique and/or approach to the sacroiliac joint, which may in the opinion of the Primary Investigator confound measurement of outcome variables;
  6. Has a medical disorder or is receiving medications that would be expected to interfere with osteogenesis;
  7. Has active , or patient with a history of any malignancy (except non-melanoma skin cancer) with recurrence within 5 years or surgery;
  8. Has active local or systemic infection or history of local or systemic infection, immune-deficiency, uncontrolled medical conditions, which in the opinion of the Investigator may increase patient risk or confound fusion results;
  9. Has >40%;
  10. Has history of tobacco smoking within 6 months prior to operation;
  11. Has history of alcoholism, medication or drug abuse, psychosis, is a prisoner, and/or has a personality disorder, poor motivation, emotional or intellectual issues that would likely make the patient unreliable for participation in the study;
  12. Has history of diabetes;
  13. Are participating in any other clinical trial;
  14. Patient is an employee (or family members of employees) of the PI/site or Sponsor; or
  15. Patient is limited or non-reader (e.g., blind, illiterate)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
25 participants (estimated)
Patient registry
No

Interventions

  • ProcedureSiJoin® Transfixing Sacroiliac Fusion Device

    Sacroiliac Fusion

06

What researchers measure

Primary outcomes

  1. Fusion Status/Evaluation

    Evaluate the fusion status of SI Joints using CT scans with a grading system based on: 1. Complete fusion; or 2. No fusion.

    Time frame: 12 Months

  2. Visual Analog Scale (VAS) Reduction

    Scale: 0 (No Pain) - 10 (Worst Pain Possible) Composite endpoint of reduction from baseline in VAS back pain score by at least 2 points.

    Time frame: 2-3 weeks, 3 Months, 6 Months, 12 Months

Secondary outcomes

  1. Ease of Use

    Assess the ease of use of the SiJoin® Fusion System Scale: 0 (Easy) - 10 (Extremely Difficult)

    Time frame: 12 months

  2. Adverse Avents

    Monitor the occurrence of adverse events related or possibly related to the use of the SiJoin® Fusion System;

    Time frame: 12 months

  3. Subsequent Surgical Interventions

    Monitor the occurrence of subsequent surgical intervention at the target sacroiliac joint(s).

    Time frame: 12 months

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2023 (actual). Primary completion is estimated for Jan 2024, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2023
First posted
Feb 6, 2023
StartActual
Jan 19, 2023
Primary completionEst.
Jan 18, 2024
CompletionEst.
Mar 31, 2025
Last update
Jul 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05712850
Lead sponsor
VG Innovations, LLC
Responsible party
Sponsor
First posted
Feb 6, 2023
Start date
Jan 19, 2023
Primary completion
Jan 18, 2024 (estimated)
Completion
Mar 31, 2025 (estimated)
Last update
Jul 24, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion